Stock Price & Analysis

Based on the analysis of Regeneron Pharmaceuticals (REGN), the stock presents a mixed outlook. While it has a high value score and some positive analyst ratings, it faces challenges from legal setbacks and revenue pressures.

Buy or Sell Recommendation:
Hold REGN stock as the mixed analyst ratings and current technical indicators suggest caution.

Regeneron Pharmaceuticals (REGN) is expected to reach a price of $870 by the end of 2025. This prediction is based on the company's strong pipeline and collaborations, particularly with Dupixent, which is expected to drive growth despite Eylea sales pressure. Analysts maintain an average price target of $903, reflecting optimism in Regeneron's long-term potential.

The S1 support level for REGN Stock is $622.19 ,The R1 resistant level for REGN Stock is $667.9.

As of the end of day on 2025-04-01, the price of REGN Stock was $619.

The target price for REGN Stock according to analyst rating is 956.25, with the highest price target at 1,182 and the lowest at 575.00. Analysts have a Strong Buy rating on REGN Stock overall.

The market cap of REGN is $67.5B.

Analysis and Insights

To determine if Regeneron Pharmaceuticals (REGN) is overvalued, we analyze its financial metrics, recent performance, and market sentiment.

Valuation Metrics:

• P/E Ratio: 18.58 (Q4 2024)
• EV/EBITDA: 15.14 (Q4 2024)
• P/S Ratio: 5.77 (Q4 2024)
• P/B Ratio: 4.14 (Q4 2024)

These metrics suggest REGN is trading at a premium compared to industry averages, indicating potential overvaluation.

Revenue and Profitability:

• Total Revenue: $3.789B (Q4 2024), showing steady growth.
• Net Income: $917.7M (Q4 2024), down from previous quarters, signaling margin compression.

Technical Analysis:

The stock is in a bearish trend with an RSI of 33.98, indicating oversold conditions. The MACD is negative, and the stock is below its 50 and 200-day moving averages.

Analyst Sentiment:

Analysts are mixed, with some downgrading due to Eylea pressures and others maintaining a buy rating on pipeline strength.

Recent News Impact:

A court ruling against REGN's Eylea biosimilar injunction caused a 3% stock drop, highlighting competitive risks.

Conclusion:

While REGN shows growth potential, its high valuation and margin challenges suggest caution. Investors should monitor pipeline progress and cost management.

Regeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company. The Company invents, develops, manufactures, and commercializes medicines for people with serious diseases. Its products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, hematologic conditions, infectious diseases, and rare diseases. It helps in accelerating and improving the traditional drug development process through its VelociSuite technologies. Its marketed products include EYLEA (aflibercept) Injection; Dupixent (dupilumab) Injection; Libtayo (cemiplimab) Injection; Praluent (alirocumab) Injection; REGEN-COV; Kevzara (sarilumab) Injection, and others. The Company’s solid tumor and other oncology and autoimmune cell therapy programs include the bbT369 program in B-NHL, SC-DARIC33 in AML, MUC16 in ovarian cancer, MAGE-A4, autoimmune, and several unnamed targets.

Based on Regeneron Pharmaceuticals' strong pipeline, including Dupixent and Libtayo, and its robust R&D capabilities, the stock is expected to reach $1,200-$1,500 by 2030. This prediction is supported by the company's history of successful drug development and its potential to expand in growing markets like immunology and oncology.

REGN has a total of 13450 employees.